---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-057696"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2021-11-19T23:59:59+00:00"
generated_at: "2026-06-28T06:35:20.417863+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics appoints two new directors and lead independent director

## Summary
- Director Peter Moldt resigned from Board and Compensation Committee; no disagreement.
- Board expanded from 8 to 9; appointed Brian O'Callaghan and Frank Lee as Class I directors.
- O'Callaghan named chair of Compensation Committee; Lee joins Nominating and Corporate Governance Committee.
- Each new director received initial option for 27,860 shares, annual option for 13,930 shares, and cash retainers.
- Existing director Jim Healy appointed as lead independent director.

## SEC filing metadata
- accession: 0001564590-21-057696
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2021-11-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/0001564590-21-057696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/bolt-8k_20211115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-057696
- JSON: https://secwatch.observer/filing/0001564590-21-057696.json
- Plain text: https://secwatch.observer/filing/0001564590-21-057696.txt

## Key facts
- Executive change
  Peter Moldt resigned as Director at Bolt Biotherapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On November 15, 2021, Peter Moldt, a director of Bolt Biotherapeutics, Inc. (the “Company”) resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/0001564590-21-057696-index.htm
- Executive change
  Frank Lee was appointed as Director at Bolt Biotherapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: The Board then appointed Brian O’Callaghan and Frank Lee to the Board as Class I directors of the Company, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/0001564590-21-057696-index.htm
- Executive change
  Jim Healy was appointed as Lead Independent Director at Bolt Biotherapeutics, Inc..
  - Action: appointed
  - Role: Lead Independent Director
  source text: the Board appointed Jim Healy, an existing member of the Board, to serve as the lead independent director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/0001564590-21-057696-index.htm
- Executive change
  Brian O'Callaghan was appointed as Director at Bolt Biotherapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: The Board then appointed Brian O’Callaghan and Frank Lee to the Board as Class I directors of the Company, effective immediately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000156459021057696/0001564590-21-057696-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.